MGI Pharma (MOGN) To Consider Strategic Alternatives
Tweet
Share
E-mail
MGI Pharma (Nasdaq: MOGN) released a statement this morning stating that its Board of Directors has authorized a review of possibly strategic alternatives. MGI Pharma would not disclose any more information detailing what "strategic alternatives" means.
For the span of the review, MGI Pharma has hired Lehman Brothers as its exclusive financial advisor. Additionally, MGI commented that there are no guarantees that anything will come from this review.
Investors are loving the news today, sending the stock higher by $4, or about 14%. Shares of MGI Pharma have hit a new 52-week high at $35.00 today, which also marks an all-time high for the Company.
MGI Pharma, Inc., a biopharmaceutical company, engages in the discovery, acquisition, development, and commercialization of proprietary pharmaceutical products in the areas of oncology and acute care in the United States.
For the span of the review, MGI Pharma has hired Lehman Brothers as its exclusive financial advisor. Additionally, MGI commented that there are no guarantees that anything will come from this review.
Investors are loving the news today, sending the stock higher by $4, or about 14%. Shares of MGI Pharma have hit a new 52-week high at $35.00 today, which also marks an all-time high for the Company.
MGI Pharma, Inc., a biopharmaceutical company, engages in the discovery, acquisition, development, and commercialization of proprietary pharmaceutical products in the areas of oncology and acute care in the United States.
You May Also Be Interested In
- Mattel (MAT) draws takeover interest from Authentic Brands - WSJ
- Brady sells French first-aid unit Securimed for ~$59 million
- Liquidity Services buys Invaluable for $80M in cash
Create E-mail Alert Related Categories
Insiders' Blog, Mergers and Acquisitions, RumorsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
